vs
Sprinklr, Inc.（CXM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Sprinklr, Inc.的季度营收约是再鼎医药的1.7倍（$219.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.2%），Sprinklr, Inc.自由现金流更多（$19.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.2%）
Sprinklr是美国的一家SaaS企业，专注于客户体验管理（CXM）平台研发。其同名产品整合了社媒营销、社交广告、内容管理、团队协作、员工倡导、客户服务、社媒调研与监测等多类应用模块，为企业提供全链路的客户体验管理解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CXM vs ZLAB — 直观对比
营收规模更大
CXM
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出8.0%
9.2%
自由现金流更多
CXM
多$46.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
6.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.1M | $127.1M |
| 净利润 | $2.9M | — |
| 毛利率 | 66.4% | 51.0% |
| 营业利润率 | 5.3% | -54.6% |
| 净利率 | 1.3% | — |
| 营收同比 | 9.2% | 17.1% |
| 净利润同比 | -72.2% | — |
| 每股收益（稀释后） | $0.01 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXMZLAB
| Q4 25 | $219.1M | $127.1M | ||
| Q3 25 | $212.0M | $115.4M | ||
| Q2 25 | $205.5M | $109.1M | ||
| Q1 25 | $202.5M | $105.7M | ||
| Q4 24 | $200.7M | $108.5M | ||
| Q3 24 | $197.2M | $101.8M | ||
| Q2 24 | $196.0M | $100.1M | ||
| Q1 24 | $194.2M | $87.1M |
净利润CXMZLAB
| Q4 25 | $2.9M | — | ||
| Q3 25 | $12.6M | $-36.0M | ||
| Q2 25 | $-1.6M | $-40.7M | ||
| Q1 25 | $98.7M | $-48.4M | ||
| Q4 24 | $10.5M | — | ||
| Q3 24 | $1.8M | $-41.7M | ||
| Q2 24 | $10.6M | $-80.3M | ||
| Q1 24 | $21.1M | $-53.5M |
毛利率CXMZLAB
| Q4 25 | 66.4% | 51.0% | ||
| Q3 25 | 68.2% | 59.5% | ||
| Q2 25 | 69.5% | 60.6% | ||
| Q1 25 | 71.0% | 63.6% | ||
| Q4 24 | 71.2% | 61.5% | ||
| Q3 24 | 72.6% | 64.1% | ||
| Q2 24 | 73.9% | 64.9% | ||
| Q1 24 | 75.5% | 61.4% |
营业利润率CXMZLAB
| Q4 25 | 5.3% | -54.6% | ||
| Q3 25 | 7.7% | -42.3% | ||
| Q2 25 | -0.9% | -50.3% | ||
| Q1 25 | 5.2% | -53.3% | ||
| Q4 24 | 3.9% | -62.6% | ||
| Q3 24 | -0.0% | -66.6% | ||
| Q2 24 | 2.9% | -76.0% | ||
| Q1 24 | 9.5% | -80.7% |
净利率CXMZLAB
| Q4 25 | 1.3% | — | ||
| Q3 25 | 5.9% | -31.2% | ||
| Q2 25 | -0.8% | -37.3% | ||
| Q1 25 | 48.7% | -45.8% | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 0.9% | -40.9% | ||
| Q2 24 | 5.4% | -80.2% | ||
| Q1 24 | 10.9% | -61.4% |
每股收益（稀释后）CXMZLAB
| Q4 25 | $0.01 | $-0.05 | ||
| Q3 25 | $0.05 | $-0.03 | ||
| Q2 25 | $-0.01 | $-0.04 | ||
| Q1 25 | $0.35 | $-0.04 | ||
| Q4 24 | $0.04 | $-0.09 | ||
| Q3 24 | $0.01 | $-0.04 | ||
| Q2 24 | $0.04 | $-0.08 | ||
| Q1 24 | $0.07 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $558.1M | $715.5M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CXMZLAB
| Q4 25 | $189.6M | $689.6M | ||
| Q3 25 | $125.4M | $717.2M | ||
| Q2 25 | $126.4M | $732.2M | ||
| Q1 25 | $145.3M | $757.3M | ||
| Q4 24 | $93.2M | $779.7M | ||
| Q3 24 | $119.1M | $616.1M | ||
| Q2 24 | $126.8M | $630.0M | ||
| Q1 24 | $164.0M | $650.8M |
股东权益CXMZLAB
| Q4 25 | $558.1M | $715.5M | ||
| Q3 25 | $543.4M | $759.9M | ||
| Q2 25 | $639.8M | $791.7M | ||
| Q1 25 | $612.1M | $810.8M | ||
| Q4 24 | $497.0M | $840.9M | ||
| Q3 24 | $469.0M | $667.7M | ||
| Q2 24 | $610.9M | $704.2M | ||
| Q1 24 | $679.7M | $762.2M |
总资产CXMZLAB
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $970.3M | $1.2B | ||
| Q3 24 | $983.8M | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.2B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 9.0% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 6.87× | — |
| 过去12个月自由现金流最近4个季度 | $142.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CXMZLAB
| Q4 25 | $20.0M | $-26.0M | ||
| Q3 25 | $34.8M | $-32.0M | ||
| Q2 25 | $83.8M | $-31.0M | ||
| Q1 25 | $5.4M | $-61.7M | ||
| Q4 24 | $9.2M | $-55.8M | ||
| Q3 24 | $21.3M | $-26.8M | ||
| Q2 24 | $41.7M | $-42.2M | ||
| Q1 24 | $17.3M | $-90.1M |
自由现金流CXMZLAB
| Q4 25 | $19.8M | $-26.7M | ||
| Q3 25 | $34.4M | $-35.0M | ||
| Q2 25 | $83.5M | $-33.9M | ||
| Q1 25 | $4.6M | $-63.2M | ||
| Q4 24 | $8.2M | $-58.4M | ||
| Q3 24 | $19.8M | $-28.2M | ||
| Q2 24 | $39.2M | $-42.9M | ||
| Q1 24 | $15.2M | $-91.1M |
自由现金流率CXMZLAB
| Q4 25 | 9.0% | -21.0% | ||
| Q3 25 | 16.2% | -30.4% | ||
| Q2 25 | 40.6% | -31.1% | ||
| Q1 25 | 2.3% | -59.9% | ||
| Q4 24 | 4.1% | -53.8% | ||
| Q3 24 | 10.1% | -27.7% | ||
| Q2 24 | 20.0% | -42.9% | ||
| Q1 24 | 7.9% | -104.5% |
资本支出强度CXMZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 0.5% | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.3% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率CXMZLAB
| Q4 25 | 6.87× | — | ||
| Q3 25 | 2.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 11.58× | — | ||
| Q2 24 | 3.92× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
